Download presentation
Presentation is loading. Please wait.
Published by란 좌 Modified over 5 years ago
1
Comparison of Neoadjuvant Chemotherapy Followed by Surgery to Upfront Surgery for Thymic Malignancy
Samina Park, MD, In Kyu Park, MD, PhD, Young Tae Kim, MD, PhD, Geun Dong Lee, MD, PhD, Dong Kwan Kim, MD, PhD, Jong Ho Cho, MD, PhD, Yong Soo Choi, MD, PhD, Chang Young Lee, MD, Jin Gu Lee, MD, PhD, Chang Hyun Kang, MD, PhD The Annals of Thoracic Surgery Volume 107, Issue 2, Pages (February 2019) DOI: /j.athoracsur Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions
2
Fig 1 The proportion of downstaging was (A) 26.5% (27 of 102) in the group with upfront surgery and was (B) 23.5% (24 of 102) in the group with neoadjuvant chemotherapy, followed by resection. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions
3
Fig 2 (A) Overall survival and (B) recurrence-free survival curves of patients who underwent neoadjuvant chemotherapy (NC), followed by resection, and upfront surgery (US). The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions
4
Fig 3 (A) Overall survival and (B) recurrence-free survival curves in pathologic TNM stage III. (NC = neoadjuvant chemotherapy, followed by resection; US = upfront surgery.) The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions
5
Fig 4 (A) Overall survival and (B) recurrence-free survival curves in patients with pathologic TNM stage IV. (NC = neoadjuvant chemotherapy, followed by resection; US = upfront surgery.) The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2019 The Society of Thoracic Surgeons Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.